Roche’s Vismodegib Meets Main Goal of Advanced Skin-Cancer Study

Roche Holding AG (ROG)’s experimental vismodegib treatment helped patients with a form of skin cancer known as advanced basal cell carcinoma, according to a study presented today at the European Multidisciplinary Cancer Congress in Stockholm.

The drug shrunk tumors and healed lesions in patients whose cancer had progressed too far to be removed with surgery, Roche said in a statement Sept. 12.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.